|
Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial. |
|
|
Honoraria - Janssen Diagnostics |
Research Funding - Janssen Diagnostics |
|
|
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Pfizer; Roche |
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Janssen Diagnostics (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); Sanofi/Aventis (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
Honoraria - Amgen; Celgene; Novartis; Pfizer; Roche |
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche Pharma AG |
|
|
Consulting or Advisory Role - Amgen; Novartis; Roche |
Research Funding - Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Celgene; Novartis; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Pfizer (Inst); Roche Pharma AG (Inst) |
Research Funding - Celgene (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Amgen; Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche Pharma AG |
Research Funding - Janssen Oncology (Inst); Novartis (Inst); Roche Pharma AG (Inst) |
|
|
Honoraria - Agena Bioscience; Novartis; Pfizer |
Consulting or Advisory Role - Novartis; Roche; Sanofi; WntResearch |
Research Funding - Janssen Diagnostics |
Patents, Royalties, Other Intellectual Property - Application no. WO2016 128125A1 |
Travel, Accommodations, Expenses - Agena Bioscience; Novartis; Pfizer |
|
|
No Relationships to Disclose |